Owners, management and financials
CVR: 39905094
Secondary names: Myoderm ApS
Previous names: Myoderm ApS
EUR 1,009,020
Gross profit
Net result: EUR 580,466
Myonex, LLC (100%)
CVR · view owners
Gregory Thomas Lavin, Michael Allen Cohen
CVR · view management
Active
Founded 28 September 2018
CVR · view overview
No headcount reported
Director role ended: James Whitfield Lovett
CVR · 29/06/2026
View the full event history
Myonex ApS is a Danish company of the type Anpartsselskab based in København Ø, founded in 2018. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The company was previously named Myoderm ApS. The management consists of Gregory Thomas Lavin and Michael Allen Cohen. The company is owned by Myonex, LLC. In 2025, the company reported a gross profit of EUR 1,009,020 and a net result of EUR 580,466 compared with EUR 2,155,499 the year before. Equity in the 2025 report amounted to EUR 19,516,469.
Source: annual report 2025, Danish Business Authority
Myonex ApS demonstrates strong financial health, characterized by significant profitability and a robust equity position. In 2025, the company reported a gross profit of 1,009,020 EUR and a profit of 580,466 EUR, following a trend of increasing profits over the previous years, peaking at 8,755,907 EUR in 2022. The equity has consistently grown, reaching 19,516,469 EUR in 2025, indicating a solid foundation for future investments. However, the absence of revenue figures raises concerns about transparency in financial reporting. Overall, Myonex ApS is well-positioned within the medicinal and healthcare supply industry, benefiting from strong margins and a growing equity base.
AI-generated summary · Generated 15/08/2026
Selskabets formål er indkøb, distribution og styring af komparatormedicin og farmaceutiske forsyninger til kliniske forsøg, herunder bioteknologiske studier, og anden hertil forbundet aktivitet.
Source: annual reports filed with the Danish Business Authority.
| Period | Gross Profit | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 202501/01/2025 – 31/12/2025 | 1 mio. EUR | 580 t. EUR | 20.1 mio. EUR | 19.5 mio. EUR | - | |
| 202401/01/2024 – 31/12/2024 | 2.6 mio. EUR | 2.2 mio. EUR | 19.3 mio. EUR | 18.9 mio. EUR | - | |
| 202301/01/2023 – 31/12/2023 | 2.7 mio. EUR | 1.9 mio. EUR | 19.9 mio. EUR | 16.8 mio. EUR | - | |
| 202201/01/2022 – 31/12/2022 | 11.4 mio. EUR | 8.8 mio. EUR | 17.1 mio. EUR | 14.9 mio. EUR | - | |
| 202101/01/2021 – 31/12/2021 | 8.1 mia. EUR | 6.2 mia. EUR | 18.1 mia. EUR | 6.1 mia. EUR | - | |
| 202001/01/2020 – 31/12/2020 | -104 t. EUR | -105 t. EUR | 3.7 mio. EUR | -179 t. EUR | - |
Screen owners and management against the Danish FSA's official PEP lists
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningThe CVR number of Myonex ApS is 39905094.
Myonex ApS is owned by Myonex, LLC.
The management of Myonex ApS consists of Gregory Thomas Lavin and Michael Allen Cohen.
In 2025, Myonex ApS reported a gross profit of EUR 1,009,020.
Myonex ApS was founded on 28 September 2018.
Myonex ApS is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler (industry code 464610).
Claim this page to add your logo and social links. Free to get started.
Myonex ApS has published its annual report for 2025. Gross profit came to DKK 1,009,020, and the net result was DKK 580,466.
As of June 29, 2026, James Whitfield Lovett has stepped down as director of Myonex ApS.
Myonex ApS has published its annual report for 2024. Gross profit came to DKK 2,591,932, and the net result was DKK 2,155,499.
Myonex ApS has published its annual report for 2023. Gross profit came to DKK 2,653,832, and the net result was DKK 1,909,497.
Myonex ApS has published its annual report for 2022. Gross profit came to DKK 11,411,359, and the net result was DKK 8,755,907.
As of October 17, 2022, James Whitfield Lovett is registered as director of Myonex ApS.
As of October 17, 2022, Gregory Thomas Lavin is registered as director of Myonex ApS.
Myonex ApS has published its annual report for 2021. Gross profit came to DKK 8,057,814,000, and the net result was DKK 6,237,759,000.
As of January 5, 2022, AIDER Godkendt Revisionsaktieselskab has been appointed auditor of Myonex ApS.
Myonex ApS has published its annual report for 2020. Gross profit came to DKK -104,398, and the net result was DKK -104,968.
On September 21, 2020, the company changed its name from Myoderm ApS to Myonex ApS.
Myonex ApS has published its interim report for the period September 28, 2018 to December 31, 2019.
As of September 28, 2018, Michael Allen Cohen is registered as director of Myonex ApS.
As of September 28, 2018, is registered as an owner of Myonex ApS with an ownership share of 100%.
Myonex ApS was founded on September 28, 2018.
Uneven Bits ApS is an independent IT consultancy founded and operated by Klaus Byskov Pedersen. With deep expertise in software architecture and systems design, I help organizations build robust, scalable, and maintainable technical solutions. Whether you need strategic guidance on technology decisions, hands-on architecture work, or help navigating complex technical challenges, I bring focused expertise and a practical approach to every engagement.
Selskabets formål er at udøve virksomhed med handel og service samt aktiviteter i tilknytning hertil.
Selskabets formål er IT- og kommunikationsvirksomhed samt virksomhed i øvrigt, der efter bestyrelsens skøn står i forbindelse hermed.
Selskabets formål er at udøve virksomhed med handel og service samt aktiviteter i tilknytning hertil.
Selskabets formål er at udvikle, markedsføre, sælge og implementere software produkter til brug ved indkøbsstyring og dermed efter bestyrelsens skøn beslægtet virksomhed
Companies in the same industry and area
CVR 46788176
CVR 45929698
CVR 19064301
CVR 37726508
CVR 44420449
